Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has been postmenopausal for at least 5 years~* Has taken or is taking alendronate~* Agrees not to use medications for osteoporosis other than what is provided by the study~Exclusion Criteria:~* Has a history or evidence of hip fracture~* Has a history of cancer within 5 years of screening, except certain skin or cervical cancers.~* Has active parathyroid disease~* Has a history of thyroid disease not adequately controlled by medication~* Is taking anti-seizure medication and has abnormal calcium metabolism~* Has received any bisphosphonate other than alendronate for 20% of the last 3 years, or within 3 months of screening

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Odanacatib 50 mg (Type: EXPERIMENTAL): Odanacatib 50 mg tablets once weekly for 24 months. Vitamin D3 (dietary supplement), two 2800 IU tablets, taken once weekly for 24 months. Participants received calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to odanacatib 50 mg tablets once weekly for 24 months. Vitamin D3 (dietary supplement), two 2800 IU tablets, taken once weekly for 24 months. Participants received calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).